Abstract

Introduction: Although rare, locally progressed breast cancer is a major obstacle for clinicians. This study was conducted because there is a direct correlation between the pathological response to neoadjuvant chemotherapy and disease free survival. This study was out to evaluate the histological impact of neoadjuvant chemotherapy on breast cancer patients with locally advanced disease. Material and Methods: This study was observational based study. The research was carried out at the Department of General Surgery, Deccan College of Medical Sciences, Hyderabad, Telangana, India. The study was done from September 2022 to July 2023. A total of twenty-five people were used as subjects in this research. Modified radical mastectomy was performed after clinical evaluation of tumour response and patient follow-up. Pathological reaction was assessed and notes were made on the specimen. Result: People in their 50s and 60s made up the bulk of the population. The majority of the 30 patients with locally advanced cancer (73%), ranging from stage IIIA to stage IIIB, were men.Nearly half of the patients tested positive for oestrogen receptors but negative for HER2, and a quarter of those individuals tested positive for all three.Everyone who tested positive for HER 2 was also considered to be a triple negative. Both the ER and PR positive tumour percentages were 67%.Forty percent of tumours tested positive for HER2. Possible explanations for the low response rate and high rate of ER positive include the fact that 83% of patients did not react to NACT and only 17% demonstrated a pathological response. Conclusion: Better prognosis may be possible if we could determine which tumours would respond best to which treatments. Recent developments in cancer biology and genetic profiling have the potential to revolutionise the clinical management of LABC by allowing for a more targeted and personalised approach.

Description